• Investor Home
  • Apollo Endosurgery Features Industry-Leading Endoscopic Procedure Portfolio at Digestive Disease Week® 2017 Conference (DDW)

Apollo Endosurgery Features Industry-Leading Endoscopic Procedure Portfolio at Digestive Disease Week® 2017 Conference (DDW)

Tuesday, May 2, 2017 3:57 pm CDT

Public Company Information:


AUSTIN, Texas--(BUSINESS WIRE)--Apollo Endosurgery, Inc. (“Apollo”) (NASDAQ:APEN), a leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced its participation during Digestive Disease Week 2017. DDW will be held May 6-9, 2017 at McCormick Place in Chicago, Illinois.

Over 35 clinical abstracts will be presented on Apollo’s endo-bariatric products which include the OverStitch™ Endoscopic Suturing System and the ORBERA® Intragastric Balloon. These clinical abstracts will include statistical proof points supporting methods to improve the efficiency and effectiveness of both products, as well as research into possible future indications.

During the conference, DDW will host several hands-on workshops including sessions that feature ORBERA® and OverStitch™ technologies. In addition, the Apollo Mobile Learning Center will be in Chicago to support hands-on physician training. The Apollo Mobile Learning Center is a state-of-the-art mobile training facility that allows for advanced endoscopic training programs to be conducted locally. These sessions further Apollo’s mission to develop safe, effective, innovative and less-invasive solutions for bariatric and gastrointestinal therapies.

To learn more about ORBERA® and OverStitch™, please visit Apollo Endosurgery at booth #2204 during the conference.


ORBERA® is an incision-less, non-surgical weight loss solution designed for adult patients suffering from obesity, who are not appropriate for or considering invasive surgery, but for whom diet and exercise or pharmaceutical interventions have not worked.

In a non-surgical (endoscopic) procedure, the thin and deflated ORBERA® balloon is placed into the stomach. It is then filled with saline until it’s about the size of a grapefruit. The procedure typically takes about 20 to 30 minutes and the patient can generally go home the same day. At six months, through another non-surgical, the ORBERA® balloon is deflated and then removed.

Once the balloon is in place, the patient receives an individually tailored support program through the ORBERA® Managed Weight Loss System team of experts to help keep them motivated, coordinate their program and help them work through weight loss barriers to meet their long-term weight loss goals. Coaching takes place over 12 months, even though the balloon is removed after six months. The program is designed to help the patient develop sustainable, healthy habits that will help keep weight off over time.

For more than 20 years, the global medical community has been using intragastric balloons from the makers of ORBERA® to help thousands of people lose weight. More than 220,000 ORBERA® balloons have been distributed worldwide in over 80 countries.

For additional information regarding ORBERA®, please visit orbera.com.

For full safety information please visit orbera.com/dfu, talk with your doctor, or call Apollo Customer Support at 1-855-MYORBERA.

About OverStitch™

The OverStitch™ endoscopic suturing system enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures from a flexible endoscope. This new technology enables a secure approximation of tissue endoscopically and a wide range of less invasive solutions for physicians who treat defects in both the upper and lower GI tract of their patients. Additionally, physicians are leveraging endoscopic suturing to perform a variety of advanced bariatric procedures. For more information regarding OverStitch™ go to: apolloendo.com.

About Apollo Endosurgery, Inc.

Apollo Endosurgery, Inc. is a medical device company focused on less invasive therapies for the treatment of obesity, a condition facing over 600 million people globally, as well as other gastrointestinal disorders. Apollo’s device based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 80 countries today.

Apollo’s common stock is traded on NASDAQ Global Market under the symbol "APEN." For more information regarding Apollo Endosurgery, go to: apolloendo.com.

© 2017 Apollo Endosurgery, Inc. All rights reserved. Any third-party trademarks used herein are the property of their respective owners.


Apollo Endosurgery, Inc.
Jen Cook, 512-279-5158

Business Wire InvestorHQ℠